PPAR
Peroxisome proliferator-activated receptors
PPARs (Peroxisome proliferator-activated receptors) are ligand-activated transcription factors of nuclear hormone receptor superfamily comprising of the following three subtypes: PPARα, PPARγ, and PPARβ/δ. PPARs play essential roles in the regulation of cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), and tumorigenesis of higher organisms. All PPARs heterodimerize with the retinoid X receptor (RXR) and bind to specific regions on the DNA of target genes. Activation of PPAR-α reduces triglyceride level and is involved in regulation of energy homeostasis. Activation of PPAR-γ enhances glucose metabolism, whereas activation of PPAR-β/δ enhances fatty acids metabolism.
PPAR Isoform Specific Products
All Product Categories
-
PPAR Inhibitors
(105)
View all products
-
PPAR Agonists
(336)
View all products
-
PPAR Antagonists
(30)
View all products
-
PPAR Activators
(168)
View all products
-
PPAR Modulators
(41)
View all products
-
PPAR Inducers
(6)
View all products
-
PPAR Controls
(3)
View all products
-
PPAR Ligands
(4)
View all products
-
Peroxisome Proliferator-activated Receptor Proteins
(11)
View all products
-
PPAR alpha Proteins
(2)
View all products
-
PPAR gamma Proteins
(7)
View all products
-
PPAR-delta Proteins
(2)
View all products
-
PPAR Related Products (737)
Related Products (737)
-
Recombinant Proteins (11)
-
Antibodies (4)
-
PPAR Isoform Comparison
-
Petasin
0 ImagesCat. No.: HY-N10612CAS No.: 26577-85-5Petasin inhibits adipogenesis in cell 3T3-F442A with an IC50 of 0.95 μM. Petasin inhibits the expression of lipid synthesis factors ACC1, FAS and SCD1 by inhibiting transcription factors PPARγ and C/EBPα, as well as targeting TRPA1 and TRPV1 channels . Petasin inhibits mitochondrial complex I, thereby inhibiting tumor growth and metastasis. Petasin activates AMPK signaling pathway, participating in regulation of glucose and lipid metabolism. Petasin is orally active.
-
GW 590735 (Standard)
0 ImagesGW 590735 (Standard) is the analytical standard of GW 590735 (HY-106278). This product is intended for research and analytical applications. GW 590735 is a potent and selective PPARα agonist. GW 590735 showsEC50=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia.
-
N-Desmethyl rosiglitazone
0 ImagesCat. No.: HY-118788CAS No.: 257892-31-2Synonyms: SB 237216N-Desmethyl rosiglitazone (SB 237216) is a metabolite of Rosiglitazone (HY-17386), generated through demethylation by the cytochrome P450 enzyme system in liver microsomes. It retains partial PPARγ agonist activity and supports studies on the metabolism and pharmacokinetics of Rosiglitazone (HY-17386).
-
SR-1903
0 ImagesCat. No.: HY-138007CAS No.: 1414248-06-8
-
AD-5075
0 ImagesCat. No.: HY-113655CAS No.: 103788-05-2
-
MK-886 (Standard)
0 ImagesCat. No.: HY-14166RCAS No.: 118414-82-7Synonyms: L 663536 (Standard)MK-886 (Standard) is the analytical standard of MK-886. This product is intended for research and analytical applications. MK-886 (L 663536) is a potent, cell-permeable and orally active FLAP (IC50 of 30 nM) and leukotriene biosynthesis (IC50s of 3 nM and 1.1 μM in intact leukocytes and human whole blood, respectively) inhibitor. MK-886 is also a non-competitive PPARα antagonist and can induce apoptosis.
-
BMS-687453 (Standard)
0 ImagesCat. No.: HY-10678RCAS No.: 1000998-59-3BMS-687453 (Standard) is the analytical standard of BMS-687453 (HY-10678). This product is intended for research and analytical applications. BMS-687453 is a potent and selective PPARα agonist, with an EC50 and IC50 of 10 nM and 260 nM for human PPARα and 4100 nM and >15000 nM for PPARγ in PPAR-GAL4 transactivation assays.
-
8(9)-EET
0 ImagesCat. No.: HY-160431CAS No.: 82864-43-58(9)-EET is one of the main metabolites produced by the metabolism of arachidonic acid (HY-109590) through the cytochrome P450 epoxide pathway. 8(9)-EET is an effective substrate for COX-1 and COX-2. 8(9)-EET activates PPARα in HEK293 cells and inhibits the activity of NF-κB induced by IL-1β in a PPARα-dependent and -independent manner. The (8S,9R)-isomer of 8(9)-EET ([(8S,9R)-EET]) causes vasoconstriction, thereby reducing renal plasma flow and glomerular filtration rate.
-
FK614 (Standard)
0 ImagesCat. No.: HY-101292RCAS No.: 193012-35-0FK614 (Standard) is the analytical standard of FK614 (HY-101292). This product is intended for research and analytical applications. FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes.
-
L-165041 (Standard)
0 ImagesCat. No.: HY-20019RCAS No.: 79558-09-1L-165041 (Standard) is the analytical standard of L-165041. This product is intended for research and analytical applications. L-165041 is a cell permeable PPARδ agonist, with Kis of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively, and induces adipocyte differentiation in NIH-PPARδ cells.
-
Perfluoropentanoic acid (Standard)
0 ImagesPerfluoropentanoic acid (Standard) (PFPeA (Standard)) is the analytical standard of Perfluoropentanoic acid (HY-21193). This product is intended for research and analytical applications. Perfluoropentanoic acid (PFPeA), a short-chain perfluorinated compound, serves as an important indicator of perfluorinated compound pollution in ecosystems. Perfluoropentanoic acid exhibits certain toxicity to mice.
-
PPARα/γ agonist 5
0 ImagesCat. No.: HY-167950CAS No.: 849150-59-0PPARα/γ agonist 5 is a dual PPARα/γ agonist with significant biological activity exhibited at low concentrations. The EC50 of PPARα/γ agonist 5 are 0.358μM and 1.21μM respectively, showing its potential in inhibiting type 2 diabetes and lipid metabolism disorders. PPARα/γ agonist 5 was selected for clinical development due to its high efficacy.
-
(E/Z)-Elafibranor
0 ImagesSynonyms: (E/Z)-GFT505(E/Z)-Elafibranor ((E/Z)-GFT505) is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively.
-
Cefminox sodium (Standard)
0 ImagesSynonyms: MT-141 (Standard)Cefminox (sodium) (MT-141) (Standard) is the analytical standard of Cefminox (sodium). This product is intended for research and analytical applications. Cefminox sodium is a semisynthetic cephamycin, which exhibits antibacterial activity. Cefminox sodium is a broad-spectrum, bactericidal cephalosporin antibiotic. Cefminox sodium also acts as a dual agonist of prostacyclin receptor (IP) and PPARγ. Cefminox sodium upregulates cAMP production and PTEN expression and inhibits Akt/mTOR signaling. Cefminox sodium also prevents pulmonary arterial hypertension in rat model.
-
Inolitazone
0 ImagesCat. No.: HY-14792CAS No.: 223132-37-4Synonyms: Efatutazone; CS-7017; RS5444
-
Hexadecanamide (Standard)
0 ImagesSynonyms: Palmitamide (Standard)Hexadecanamide (Standard) is the analytical standard of Hexadecanamide. This product is intended for research and analytical applications. Hexadecanamide (Palmitamide) is a fatty acid amide that has orally active anti-allergic, antioxidant, and neuroprotective effects. Hexadecanamide exerts protective effects in Staphylococcus aureus- and SARA-induced mastitis. Hexadecanamide suppresses S. aureus-induced activation of the NF-κB pathway and improves blood-milk barrier integrity. Hexadecanamide activates PPARα. Hexadecanamide enhances sperm motility in vitro. Hexadecanamide can be studied in research for mastitis and asthenozoospermia.
-
Farglitazar (Standard)
0 ImagesCat. No.: HY-105074RCAS No.: 196808-45-4Synonyms: GI262570 (Standard); GI262570X (Standard)Farglitazar (Standard) is the analytical standard of Farglitazar (HY-105074). This product is intended for research and analytical applications. Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.
-
Aminophylline (Standard)
0 ImagesAminophylline (Standard) is the analytical standard of Aminophylline (HY-B0140). This product is intended for research and analytical applications. Aminophylline is a competitive phosphodiesterase 3/4 (PDE3/4) inhibitor. Aminophylline also acts as an adenosine receptor antagonist. Aminophylline elevates intracellular cAMP levels via competitive inhibition of PDE3 and PDE4, antagonizes adenosine A1 receptor (ADORA1), regulates intracellular calcium signaling and synaptic vesicle cycling, upregulates the PPAR signaling pathway, and downregulates glutamatergic synaptic pathways simultaneously. Aminophylline can be used in research related to major depressive disorder, epilepsy, and chronic obstructive pulmonary disease (COPD).
-
Bezafibrate-13C6
0 ImagesCat. No.: HY-B0637S2Synonyms: BM15075-13C6
-
17-Oxo-7(Z),10(Z),13(Z),15(E),19(Z)-docosapentaenoic acid
0 ImagesCat. No.: HY-116115CAS No.: 1233715-33-7Synonyms: 17-Oxo-DPA; 17-Oxo-7(Z),10(Z),13(Z),15(E),19(Z)-DPA17-Oxo-7(Z),10(Z),13(Z),15(E),19(Z)-docosapentaenoic acid (17-Oxo-DPA; 17-Oxo-7(Z),10(Z),13(Z),15(E),19(Z)-DPA) is an electrophilic oxo-derivative (EFOX) of the docosahexaenoic acid (DHA) (HY-B2167). 17-Oxo-7(Z),10(Z),13(Z),15(E),19(Z)-docosapentaenoic acid is generated during inflammation by COX-2-catalyzed mechanism in activated macrophages. 17-Oxo-7(Z),10(Z),13(Z),15(E),19(Z)-docosapentaenoic acid acts as an agonist for PPARγ and a modulator for NF-κB signaling pathway, inhibits the production of pro-inflammatory cytokines and nitric oxide, and exhibits anti-inflammatory efficacy.
